Invitae has launched the Breast Cancer STAT Panel, a rapid turnaround gene panel that includes seven genes with surgical and therapeutic relevance: BRCA1, BRCA2, CDH1, PALB2, PTEN, SK11, and TP53. Mutations in these genes may influence patient and physician decisions on mastectomy versus lumpectomy, and whether to prophylactically remove the ovaries and fallopian tubes. Results of the panel can also help guide choice of chemotherapy. Turnaround time is eight to 12 calendar days. Price per indication is the same as Invitae's other tests — $950 for payors and institutions that are in contract with the company, $1,500 for third party payors that are out of network, and $475 for patients without insurance or who do not meet their insurance's criteria for coverage.